For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Meningioma Drug Treatment Study
This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grown back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
In order to participate you must meet the following criteria:
- Have a diagnosed meningioma.
- Have a SMO or NF2 tumor gene alteration (also known as mutation).
- Are at least 18 years of age.
This is a partial list of eligibility requirements.